S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Recro Pharma Stock Forecast, Price & News

+0.01 (+0.65%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
264,200 shs
Average Volume
482,077 shs
Market Capitalization
$72.72 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

Recro Pharma logo

About Recro Pharma

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.


Recro Pharma (REPH) Set to Announce Earnings on Tuesday
November 4, 2021 |  americanbankingnews.com
Recro Signs Renewable Energy Agreement With Georgia Power
September 21, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$66.50 million
Book Value
$0.95 per share


Net Income
$-27.50 million
Pretax Margin




Free Float
Market Cap
$72.72 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.86 out of 5 stars

Medical Sector

750th out of 1,391 stocks

Pharmaceutical Preparations Industry

358th out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

Is Recro Pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Recro Pharma stock.
View analyst ratings for Recro Pharma
or view top-rated stocks.

How has Recro Pharma's stock price been impacted by COVID-19?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, REPH stock has decreased by 83.0% and is now trading at $1.56.
View which stocks have been most impacted by COVID-19

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 823,800 shares, an increase of 22.5% from the October 31st total of 672,500 shares. Based on an average trading volume of 325,300 shares, the days-to-cover ratio is presently 2.5 days. Currently, 1.9% of the shares of the stock are sold short.
View Recro Pharma's Short Interest

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Friday, February 25th 2022.
View our earnings forecast for Recro Pharma

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.02. Recro Pharma had a negative trailing twelve-month return on equity of 199.98% and a negative net margin of 32.85%. During the same period in the previous year, the firm posted ($0.09) earnings per share.
View Recro Pharma's earnings history

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma updated its FY 2021 earnings guidance on Tuesday, November, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $74 million-$76 million, compared to the consensus revenue estimate of $73.82 million.

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • J. David Enloe, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Ryan D. Lake, Chief Financial Officer & Treasurer
  • Richard Sidwell, Chief Scientific Officer & Senior Vice President
  • David Smithwick, Vice President-Technical Operations
  • Cristin Grove, Senior Director-Business Development

What other stocks do shareholders of Recro Pharma own?

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Cowen Prime Advisors LLC (7.44%), Renaissance Technologies LLC (2.58%), Stephens Inc. AR (2.49%), Essex Investment Management Co. LLC (1.51%), Kornitzer Capital Management Inc. KS (1.08%) and Russell Investments Group Ltd. (1.05%). Company insiders that own Recro Pharma stock include Awm Investment Company, Inc, Ernest Nicolas, Geraldine Henwood, J David Enloe Jr, James Charles Miller, Ryan David Lake and Scp Vitalife Partners (Israel).
View institutional ownership trends for Recro Pharma

Which major investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, and Russell Investments Group Ltd.. Company insiders that have sold Recro Pharma company stock in the last year include Awm Investment Company, Inc, Ernest Nicolas, and Scp Vitalife Partners (Israel).
View insider buying and selling activity for Recro Pharma
or view top insider-selling stocks.

Which major investors are buying Recro Pharma stock?

REPH stock was purchased by a variety of institutional investors in the last quarter, including Cowen Prime Advisors LLC, Essex Investment Management Co. LLC, Stephens Inc. AR, Renaissance Technologies LLC, Boston Partners, Two Sigma Investments LP, BlackRock Inc., and Geode Capital Management LLC. Company insiders that have bought Recro Pharma stock in the last two years include J David Enloe Jr, James Charles Miller, and Ryan David Lake.
View insider buying and selling activity for Recro Pharma
or or view top insider-buying stocks.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $1.56.

How much money does Recro Pharma make?

Recro Pharma has a market capitalization of $72.72 million and generates $66.50 million in revenue each year. The specialty pharmaceutical company earns $-27.50 million in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does Recro Pharma have?

Recro Pharma employs 185 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

Where are Recro Pharma's headquarters?

Recro Pharma is headquartered at 490 LAPP ROAD, MALVERN PA, 19355.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at (484) 395-2470, via email at [email protected], or via fax at 484-395-2471.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.